ClinicalTrials.gg
RecruitingNCT07851103Updated Nov 10, 2026

A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer

A Phase 1 interventional study of BI 3968621 and ezabenlimab in Advanced Solid Tumour, sponsored by Boehringer Ingelheim. Recruiting at 10 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Updated Nov 10, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is open to adults with advanced cancer that cannot be removed by surgery or have spread to other parts of the body. The purpose of this study is to find the highest and most suitable dose of BI 3968621 that people with advanced cancer can tolerate when taken alone or with ezabenlimab. Another purpose is to find out if taking these medicines can stop tumours from growing or make tumours shrink. In this study, BI 3968621 is given to people for the first time.

The study is done in 3 parts. The parts are called Part A, Part A2, and Part B. Participants get BI 3968621 alone or in combination with ezabenlimab depending on which part they are in. Part A is done to find the highest and the most suitable dose of BI 3968621 that people with advanced cancer can tolerate. Part A2 is done to find out if taking BI 3968621, at certain dose levels, can stop or slow down tumour growth in participants with kidney cancer. Part B is done to find out how BI 3968621 is tolerated when given with ezabenlimab. BI 3968621 is taken daily as tablets. Ezabenlimab is given as an infusion into a vein once every 3 weeks.

Participants can receive study treatment for up to 2 years if they benefit and can tolerate it. During this time, they visit the study site regularly. The number of visits depends on how participants respond to and tolerate the study treatment. Researchers look at the number of participants with certain severe health problems that happen within 3 weeks after the first study treatment. The study doctors check participants' health, take note of unwanted effects, take blood samples, and check how the cancer responds to study treatment.

02

Conditions studied

  • Advanced Solid Tumour
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants ≥18 years of age and at least at the legal age of consent
  • Patients with a confirmed diagnosis of advanced, unresectable, and/or solid tumours (any type). Patients who have failed conventional treatment or for whom no therapy of proven efficacy exists or who are not eligible for established treatment options. Patients must have exhausted approved treatment options known to prolong survival for their disease
  • At least one outside of central nervous system (CNS) as defined per modified (RECIST) v1.1
  • (ECOG) performance status of 0 or 1
  • ≥3 months at the start of treatment in the opinion of the investigator
  • Patients with known are eligible, provided they meet the protocol-defined criteria
  • Patients must have adequate organ function based on haematological, hepatic, renal, and coagulation parameters Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  • Previous or concomitant other than the one treated in this trial within the past 3 years (except effectively treated malignancy considered cured by local treatment, e.g. non melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ)
  • Patient with known or spinal cord compression due to disease
  • Patients with infection or active infection (chronic or acute)
  • Patients with known history of (HIV) infection who meet protocol-defined criteria
  • Patient with active disease or a documented history of autoimmune disease, which requires systemic treatment (e.g. or drugs)
  • Patient with a diagnosis of immunodeficiency other than HIV
  • Manifestation of malabsorption or any other condition that could affect oral absorption, distribution or metabolism of the study drug Further exclusion criteria apply.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    BI 3968621 dose escalation monotherapy (Part A)

    Drug: BI 3968621

  • Experimental
    BI 3968621 dose expansion monotherapy (Part A2)

    Drug: BI 3968621

  • Experimental
    BI 3968621 + ezabenlimab dose escalation combination therapy (Part B)

    Drug: BI 3968621 · Drug: ezabenlimab

Interventions

06

What researchers measure

Primary outcomes

  1. Occurrence of dose-limiting toxicities (DLTs) during the primary DLT evaluation period (Dose escalation part A and B)

    Time frame: During the first treatment cycle, up to 21 days

  2. Objective response (OR)

    defined as best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), where BOR is determined by investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 from first administration until earliest of disease progression, death or last evaluable tumour assessment before start of subsequent anticancer therapy, lost to follow-up, or withdrawal of consent, whichever occurs first (Part A2)

    Time frame: Up to 2 years

Secondary outcomes

  1. Occurrence of treatment-emergent adverse events (AEs)

    Time frame: Up to 2 years

  2. Occurrence of dose-limiting toxicities (DLTs)

    Time frame: Up to 2 years

  3. Occurrence of drug-related AEs

    Time frame: Up to 2 years

  4. Occurrence of treatment-emergent serious adverse events (SAEs)

    Time frame: Up to 2 years

  5. Objective response (OR)

    defined as best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), where BOR is determined by investigator's assessment according to Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 from first administration until earliest of disease progression, death or last evaluable tumour assessment before start of subsequent anticancer therapy, lost to follow-up, or withdrawal of consent, whichever occurs first (part A + B)

    Time frame: Up to 2 years

  6. Duration of response (DoR)

    based on RECIST v1.1, defined as the time from first confirmed CR or PR until the earliest of progressive disease (PD) or death among patients with an OR (part A2)

    Time frame: Up to 2 years

  7. Progression-free survival (PFS)

    defined as the time from first treatment administration until tumour progression according to RECIST v1.1 or death from any cause, whichever occurs first (part A2)

    Time frame: Up to 2 years

  8. Progression-free survival (PFS) at 6 months (PFS6)

    defined as being alive and without tumour progression at 6 months from first treatment administration (part A2)

    Time frame: At 6 months

  9. Clinical Benefit (CB)

    defined as achievement of BOR of CR or PR of any duration, or stable disease (SD) of at least 6 months according to RECIST v1.1 (part A2)

    Time frame: Up to 2 years

  10. Disease control (DC)

    based on RECIST v1.1, defined as the best overall response of CR, PR, or SD from the first administration of trial medication until the earliest of PD, death, last evaluable tumour assessment before the start of subsequent anticancer therapy, loss to follow-up, or withdrawal of consent, whichever occurs first

    Time frame: Up to 2 years

  11. Immune objective response (iOR)

    as determined by investigator's assessment according to iRECIST, defined as immune BOR (iBOR) of immune CR (iCR) or immune PR (iPR), determined from date of first administration until earliest of disease progression (immune unconfirmed progressive disease \[iUPD\] that is confirmed at next radiological assessment), death, last evaluable tumour assessment before start subsequent anticancer therapy, loss to follow-up, or withdrawal of consent, whichever occurs first

    Time frame: Up to 2 years

  12. Immune DC (iDC)

    based on iRECIST v1.1, defined as the best overall response of iCR, iPR or iSD from the first administration of trial medication until the earliest of iUPD (provided that iCPD is the next time point response, i.e. progression is confirmed at the next tumour assessment), death, last evaluable tumour assessment before start of subsequent anticancer therapy, loss to follow-up, or withdrawal of consent, whichever occurs first

    Time frame: Up to 2 years

  13. Maximum measured concentration of the analyte in plasma (after the first dose in Cycle 1) (Cmax)

    Time frame: Up to Day 15 in cycle 1 (each cycle is 21 days)

  14. Area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the first dose in Cycle 1 (AUCτ,1)

    Time frame: Up to Day 15 in cycle 1 (each cycle is 21 days)

  15. Maximum measured concentration of the analyte in plasma at steady state (after the first dose in Cycle 2) (Cmax,ss)

    Time frame: Up to Day 15 in cycle 2 (each cycle is 21 days)

  16. Area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ (after the first dose in Cycle 2) (AUCτ,ss)

    Time frame: Up to Day 15 in cycle 2 (each cycle is 21 days)

07

Study locations

3 of 10 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents - upon signing of a "Document Sharing Agreement". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Sep 2030, 45 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 1, 2026
StartEst.
Nov 10, 2026was Oct 2026
Primary completionEst.
Sep 3, 2030
CompletionEst.
Sep 3, 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
10 sites changed recruiting status (7 now not yet recruiting, 3 now recruiting)
Show 10 sites
  • Florida Cancer Specialists-Sarasota-61670 · Sarasota, United Statesno status→Recruiting
  • Emory University · Atlanta, United Statesno status→Not yet recruiting
  • Thomas Jefferson University · Philadelphia, United Statesno status→Not yet recruiting
  • Sarah Cannon Research Institute-Nashville-48456 · Nashville, United Statesno status→Recruiting
  • The University of Texas MD Anderson Cancer Center · Houston, United Statesno status→Not yet recruiting
  • Universitair Ziekenhuis Gent · Ghent, Belgiumno status→Not yet recruiting
  • Institut Gustave Roussy · Villejuif, Franceno status→Not yet recruiting
  • Japanese Foundation for Cancer Research · Tokyo, Koto-ku, Japanno status→Recruiting
  • Hospital Universitari Vall d'Hebron · Barcelona, Spainno status→Not yet recruiting
  • Hospital Clinico De Valencia (INCLIVA) · Valencia, Spainno status→Not yet recruiting
across 2 updates, Oct 28, 2026 – Nov 10, 2026
Start date
Oct 26, 2026→Nov 10, 2026
Nov 10, 2026
Registered
First appeared on the registry
Oct 1, 2026
Show all 3 updates
  1. Nov 10, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Sarah Cannon Research Institute-Nashville-48456 · Nashville, United StatesNot yet recruiting→Recruiting
    • Japanese Foundation for Cancer Research · Tokyo, Koto-ku, JapanNot yet recruiting→Recruiting
    Start date Oct 26, 2026→Nov 10, 2026
    + 1 other change: verification date
  2. Oct 28, 2026
    Not yet recruiting→Recruiting
    10 sites changed recruiting status (9 now not yet recruiting, 1 now recruiting)
    Show 10 sites
    • Florida Cancer Specialists-Sarasota-61670 · Sarasota, United Statesno status→Recruiting
    • Emory University · Atlanta, United Statesno status→Not yet recruiting
    • Thomas Jefferson University · Philadelphia, United Statesno status→Not yet recruiting
    • Sarah Cannon Research Institute-Nashville-48456 · Nashville, United Statesno status→Not yet recruiting
    • The University of Texas MD Anderson Cancer Center · Houston, United Statesno status→Not yet recruiting
    • Universitair Ziekenhuis Gent · Ghent, Belgiumno status→Not yet recruiting
    • Institut Gustave Roussy · Villejuif, Franceno status→Not yet recruiting
    • Japanese Foundation for Cancer Research · Tokyo, Koto-ku, Japanno status→Not yet recruiting
    • Hospital Universitari Vall d'Hebron · Barcelona, Spainno status→Not yet recruiting
    • Hospital Clinico De Valencia (INCLIVA) · Valencia, Spainno status→Not yet recruiting
    + 1 other change: verification date
  3. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851103
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Nov 10, 2026 (estimated)
Primary completion
Sep 3, 2030 (estimated)
Completion
Sep 3, 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Boehringer Ingelheim
Contact
clintriage.rdg@boehringer-ingelheim.com
018002430127

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion